Inhibikase Therapeutics, Inc.: 10-Q filed 2021-05-17
What Inhibikase Therapeutics, Inc. reported in its quarterly report filed 2021-05-17 (fiscal Q1 2021): 27 published measures, 55 facts as tagged in accession 0001564590-21-028436.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-05-17
- Fiscal period
- fiscal Q1 2021
- Accession
- 0001564590-21-028436 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Inhibikase Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 11,874,035 | USD | |
| At 2020-12-31 | 14,782,706 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 3,837,464 | USD | |
| At 2020-12-31 | 4,998,350 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 8,036,571 | USD | |
| At 2020-12-31 | 9,784,356 | USD | |
| At 2020-03-31 | -4,701,834 | USD | |
| At 2019-12-31 | -4,490,016 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -2,637,068 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -547,440 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -3,934,220 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -255,432 | USD | 91 |
Contract revenue excluding tax
Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 1,407,165 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 270,787 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -409,662 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 250,120 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | -17,668,692 | USD | |
| At 2020-12-31 | -15,031,624 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 0 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 0 | USD | 91 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 591,124 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 139,758 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -2,625,271 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -540,015 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 11,871,252 | USD | |
| At 2020-12-31 | 14,782,706 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 11,797 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 7,425 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 3,588,553 | USD | |
| At 2020-12-31 | 4,721,889 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 715,016 | USD | |
| At 2020-12-31 | 1,720,680 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 1,600,576 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 527,688 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 2,431,860 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 283,114 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 10,059,849 | shares | |
| At 2020-12-31 | 10,050,849 | shares |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 9,609,631 | USD | |
| At 2020-12-31 | 13,953,513 | USD | |
| At 2020-03-31 | 13,145 | USD | |
| At 2019-12-31 | 18,457 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 1,243,700 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 627,399 | USD | |
| At 2020-12-31 | 632,934 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 1,216,173 | USD | |
| At 2020-12-31 | 54,837 | USD |
Current contract liabilities
Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 1,251,349 | USD | |
| At 2020-12-31 | 2,325,741 | USD |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 11,797 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 1,772 | USD | 91 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 4,870 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 332,774 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -1,008,447 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -255,922 | USD | 91 |
Inspect the source
- Entity
- Inhibikase Therapeutics, Inc. / CIK 0001750149
- Captured
- 2026-09-21T17:25:56.509Z
- SEC response SHA-256
203698bfa89561c7804b33011fdebdf3b28ff82ca1d2a96ec2c0a9014e52024e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001750149.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))